All News

Although it may not be feasible in all situations, professional sabbatical leave could be a win-win for both pharmacists and their employers.

Oral use of glucosamine hydrochloride may reduce pain related to rheumatoid arthritis.

Semaglutide (Rybelsus) is a glucagon-like peptide-1 receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

During atrial fibrillation, both of the heart's upper chambers beat chaotically and irregularly without coordination.

Kelan Thomas, PharmD, MS, associate professor of clinical sciences at Touro University California College of Pharmacy, discusses potential adverse effects and drug-drug interactions with psilocybin, MDMA, and ketamine treatment.

Lauren C. Pinter-Brown, MD, FACP, of UCI Health and Chao Family Comprehensive Cancer Center, explains what the role of the pharmacist is during the treatment of patients with advanced cutaneous T cell lymphoma.

The agency has given the greenlight to maralixibat after the ICONIC study combined with 5 years of supportive studies that demonstrated the reduction of pruritis.

Individuals who used intranasal corticosteroids prior to being infected were about 22% less likely to be hospitalized from severe COVID-19 than those who did not.

This month's case studies include questions about continuous glucose monitoring, diabetes neuropathic pain, diabetes and colds, and smoking cessation.

The researchers noted the importance of maintaining vaccination rates for conditions that can lead to respiratory issues, especially with COVID-19 cases still raising concern throughout the United States.

Rivaroxaban (Xarelto, Janssen) demonstrates a lower incidence of bleeding events in pediatric patients.

Ten quiz questions to assess your knowledge on common symptoms and treatments for obstructive sleep apnea.

T2D is associated with a higher mortality risk linked to the coronavirus than individuals with T1D.

The recommendation for managing cytopenias among patients treated with tyrosine kinase inhibitors is to discontinue treatment at the onset of grade 3 or higher.

The combination of cetuximab and encorafenib resulted in a median overall survival of 8.4 months, compared to 5.4 months in the control arm among patients with colorectal cancer.

Significant reductions in mean monthly migraine days compared with placebo were seen as early as weeks 1 through 4 in the clinical trial program for atogepant.

Although specialty pharmacies may be able to offer some of the services that a hub provider does, a hub can standardize patient and provider support across the network.

Study shows that shedding pounds potentially decreases the risk of diabetes, dyslipidemia, and high blood pressure.

Amisulpride is a selective dopamine-2 and -3 receptor antagonist that inhibits postoperative nausea and vomiting.

There are several types of bipolar disorders, including mania or hypomania and depression.

Lauren C. Pinter-Brown, MD, FACP, of UCI Health and Chao Family Comprehensive Cancer Center, addresses the areas that may need further investigation to progress advanced cutaneous T cell lymphoma treatments in the future.

The medication has met the criteria of overall survival for individuals with this type of liver cancer who were previously treated with sorafenib, Merck says.

Patients with senile dementia who have silent epileptic activity show improvement when taking this medication.

Risk stratification for survival should not dictate treatment, but stratification for thrombosis risk should play an important role in treatment decisions.

Cemiplimab-rwlc is being developed by Regeneron and Sanofi under a global collaboration agreement.

Durvalumab in combination with oleclumab reduced the risk of non-small cell lung cancer disease progression or death by 56%, whereas patients receiving durvalumab and monalizumab had a 35% reduction.

The results were compared to those in the previous Pfizer-BioNTech study in people between 16 and 25 years of age who were immunized with 30 μg doses.

The combination maintained superior OS and response benefits versus sunitinib in both patients with intermediate- and poor-risk prognostic factors, the primary endpoint population, and across all randomized patients.